ImmunityBio Analyst Price Targets

Wall Street analyst price targets and consensus rating for ImmunityBio (IBRX).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$15Upside to Avg. PT+46.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 2, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$15
May 21, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$12
May 20, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$15
May 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Apr 21, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Apr 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Mar 26, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Mar 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Mar 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Mar 12, 2026	BTIG	Jeet Mukherjee	Assumes	Buy	$13
Mar 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Mar 4, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$7→$12
Feb 23, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$10→$15
Feb 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$23
Feb 19, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$24
Feb 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$24
Jan 26, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$8→$10
Jan 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$24
Jan 23, 2026	BTIG	Justin Zelin	PT Raise	Buy	$6→$9
Jan 20, 2026	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$5→$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

BTIG analyst Jeet Mukherjee reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $12 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
BTIG Assumes ImmunityBio at Buy, Announces Price Target of $13

BTIG analyst Jeet Mukherjee assumes ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $13.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on ImmunityBio, Raises Price Target to $12

Piper Sandler analyst Edward Tenthoff reiterates ImmunityBio (NASDAQ:IBRX) with a Overweight and raises the price target from $7 to $12.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

Benzinga Newsdesk

ImmunityBio Inc

ImmunityBio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

PRO
BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

PRO
BTIG Assumes ImmunityBio at Buy, Announces Price Target of $13

PRO
Piper Sandler Reiterates Overweight on ImmunityBio, Raises Price Target to $12

PRO
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target

People Also Watch

People Also Watch

ImmunityBio Inc

ImmunityBio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

PROBTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

PROHC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

PROBTIG Assumes ImmunityBio at Buy, Announces Price Target of $13

PROPiper Sandler Reiterates Overweight on ImmunityBio, Raises Price Target to $12

PROD. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

PRO
BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

PRO
BTIG Assumes ImmunityBio at Buy, Announces Price Target of $13

PRO
Piper Sandler Reiterates Overweight on ImmunityBio, Raises Price Target to $12

PRO
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target